Rhumbline Advisers Decreases Stock Holdings in Haemonetics Corporation $HAE

Rhumbline Advisers lowered its position in shares of Haemonetics Corporation (NYSE:HAE) by 5.7% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 156,872 shares of the medical instruments supplier’s stock after selling 9,535 shares during the period. Rhumbline Advisers owned about 0.33% of Haemonetics worth $7,646,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the company. EverSource Wealth Advisors LLC boosted its holdings in shares of Haemonetics by 2,640.0% during the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 396 shares during the period. Versant Capital Management Inc boosted its holdings in Haemonetics by 216.4% in the third quarter. Versant Capital Management Inc now owns 829 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 567 shares in the last quarter. Byrne Asset Management LLC bought a new position in Haemonetics in the 3rd quarter worth $42,000. Elevation Point Wealth Partners LLC purchased a new stake in shares of Haemonetics in the 2nd quarter worth about $64,000. Finally, Hantz Financial Services Inc. boosted its stake in shares of Haemonetics by 792.1% during the 3rd quarter. Hantz Financial Services Inc. now owns 1,124 shares of the medical instruments supplier’s stock valued at $55,000 after purchasing an additional 998 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Wall Street Zen upgraded shares of Haemonetics from a “hold” rating to a “buy” rating in a report on Saturday, January 10th. Citigroup lowered their target price on Haemonetics from $88.00 to $75.00 and set a “neutral” rating for the company in a research note on Friday, February 6th. BTIG Research reaffirmed a “buy” rating and issued a $88.00 price target on shares of Haemonetics in a research note on Friday, February 6th. Raymond James Financial reissued an “outperform” rating and set a $90.00 price objective on shares of Haemonetics in a research report on Friday, November 14th. Finally, Mizuho dropped their target price on shares of Haemonetics from $90.00 to $80.00 and set an “outperform” rating on the stock in a report on Friday, February 6th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, Haemonetics presently has an average rating of “Moderate Buy” and an average target price of $84.44.

Haemonetics Price Performance

NYSE HAE opened at $61.24 on Friday. The company has a 50-day moving average price of $71.94 and a 200-day moving average price of $63.97. Haemonetics Corporation has a 52 week low of $47.31 and a 52 week high of $87.32. The company has a quick ratio of 1.15, a current ratio of 1.75 and a debt-to-equity ratio of 1.01. The firm has a market capitalization of $2.85 billion, a P/E ratio of 16.87, a PEG ratio of 1.28 and a beta of 0.28.

Haemonetics (NYSE:HAE) last announced its earnings results on Thursday, February 5th. The medical instruments supplier reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.27 by $0.04. Haemonetics had a return on equity of 27.32% and a net margin of 13.31%.The company had revenue of $338.97 million for the quarter, compared to analysts’ expectations of $331.90 million. During the same period last year, the firm earned $1.19 EPS. Haemonetics’s revenue for the quarter was down 2.7% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. Equities research analysts anticipate that Haemonetics Corporation will post 4.55 earnings per share for the current year.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.